[A24-115] Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73
Last updated 16.01.2025
Project no.:
A24-115
Commission:
Commission awarded on 26.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adjuvant treatment following complete tumour resection for adult patients with anaplastic lymphoma kinase-positive non-small cell lung cancer at high risk of recurrence
Result of dossier assessment:
- Patients for whom adjuvant platinum-based chemotherapy is suitable: Unchanged after addendum: added benefit not proven
- Patients after prior platinum-based chemotherapy or patients for whom this therapy is not suitable: Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A24-115_en
| Project no. | Title | Status |
|---|---|---|
| A24-73 | Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-01-16 A G-BA decision was published.